Roche wins CE mark for CGM, mySugr integration, presents positive clinical data
September 16, 2025
Roche announced today that it received CE mark for the integration of its Accu-Chek SmartGuide CGM with the mySugr app.
Roche announced today that it received CE mark for the integration of its Accu-Chek SmartGuide CGM with the mySugr app.
Novocure (Nasdaq:NVCR) announced today that it received regulatory approval in Japan for its Optune Lua wearable device.
The finding opens a new path for cancer treatment.
Nearly 50 new cancer therapies are approved every year. This is good news. “But for patients and their treating physicians, it is becoming increasingly difficult to keep track and to select the treatment methods from which the people affected—each with their very individual tumor characteristics—will benefit the most,” says Dr. Altuna Akalin, head of the Bioinformatics and Omics Data Science technology platform at the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB).
Researchers at Emory Goizueta Brain Health Institute and partner institutions have found new clues in the blood that could help explain why Alzheimer’s disease develops and how it affects memory.
Advance from SMART will help to better identify disease markers and develop targeted therapies and personalized treatment for diseases such as cancer and antibiotic-resistant infection.
While vaccines can be very effective for preventing viruses, like the influenza A virus (IAV), they are often strain-specific and prone to viral escape mutations. IAV alone is responsible for around 500,000 deaths worldwide each year.
Early and accurate diagnosis of dementia remains a major challenge. Standard approaches such as MRI and PET scans can provide valuable information about brain structure and function, but they are expensive, not always accessible, and often too expensive for repeated use.
Scientists have identified a natural extract that could help boost the effectiveness of cancer drugs. The insights gained from their study may help formulate new combination drug therapies, using precision medicine to target and cure cancer and improve patient outcomes.
Teleflex (NYSE:TFX) announced today that it enrolled the first patient in its DUBSTENT DIABETES trial.